Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial

Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial

Abstract Background Simvastatin therapy for patients with acute respiratory distress syndrome (ARDS) has been shown to be safe and associated with minimal adverse effects, but it does not improve clinical outcomes. The aim of this research was to report on mortality and cost-effectiveness of simvast...

Full description

Bibliographic Details
Main Authors: A. Agus, C. Hulme, R. M. Verghis, C. McDowell, C. Jackson, C. M. O’Kane, J. G. Laffey, D. F. McAuley
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Critical Care
Subjects:
Acute respiratory distress syndrome
Statins
Critical care
Cost-effectiveness
QALYs
Online Access:http://link.springer.com/article/10.1186/s13054-017-1695-0

Similar Items

Similar Items